Sound Biologics

PSB103 Clin1 (China) oncology; 5 programs Clin0 oncology; 3 programs RD oncology, autoimmune diseases

Sound Biologics is creating innovative technologies for the treatment of cancer and inflammatory diseases. The biological processes behind disease are inherently complex with therapies targeting only a single receptor or pathway unlikely to show maximal efficacy. Instead, Sound is developing technology that enables interdiction of multiple pathways by efficiently producing a single drug product that contains more than one therapeutic antibody. Sound’s approach is to use their MabPair platform that enables the development of custom-designed antibody combinations that provide the synergy of two full-antibody combinations reducing the opportunity for tumor escape and drug resistance. In addition, Sound is creating heterodimeric bispecific antibodies to generate novel therapeutic antibody candidates.

Jobs: